USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
18 Jan 2024 | 04:00 PM GMT

Do Accelerators Work to Nurture Innovation?

Anchored by:

Sophie Park
Managing Director
BAYER G4A
Jochen Hurlebaus
President & Owner
XO LIFE

Participants:

Jochen Hurlebaus President & OwnerXO Life
Jochen Hurlebaus
President & OwnerXO Life
Sophie Park Managing DirectorBayer G4A
Sophie Park
Managing DirectorBayer G4A
Xenia Riasol Cercos Sponsored Programmes Strategy ManagerHLTH
Xenia Riasol Cercos
Sponsored Programmes Strategy ManagerHLTH
Aahuti Rai NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Aahuti Rai
NED, Advisor & Venture PartnerFour Points Health | Conduit Connect
Hannes Toivanen Lead, Global Digital Ecosystems EngamentsTakeda
Hannes Toivanen
Lead, Global Digital Ecosystems EngamentsTakeda
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Shwen Gwee Member of the Advisory BoardNew Enterprise Ventures
Shwen Gwee
Member of the Advisory BoardNew Enterprise Ventures
Susanne Gruber Strategic Healthcare AdvisorIgnited Vision
Susanne Gruber
Strategic Healthcare AdvisorIgnited Vision
Timothy Graham Director Digital StrategyGSK
Timothy Graham
Director Digital StrategyGSK

About this Meeting

Accelerators play a crucial role in nurturing innovation in pharma by bringing together diverse and innovative stakeholders to create a collaborative ecosystem that fosters the exchange of ideas, expertise, and best practices most conducive to breakthrough discoveries and advancements.  
 
Accelerators are not a one-size-fits-all solution for disruptors in the digital health space.  The value of these programmes depends on factors such as mentorship quality, network relevance, and alignment with company growth needs. Furthermore, an accelerator’s success in this space relies on its ability to adapt to the ever-changing technology needs of pharma and its customers, staying ahead of emerging trends and technologies.   

Join this discussion to collectively determine how accelerators can be the best fit for innovation:   

  • What are the key benefits and potential drawbacks of participating in acceleration programmes for startups?  
  • What factors should startups consider to ensure that an acceleration programme aligns with their specific needs, goals, and values?  
  • What can pharma do to ensure that acceleration programmes benefit both entities equally? Where can pharma let accelerators bring the greatest value to digital health?  
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.